Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shawn Du

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Clinical Genitourinary Cancer|April 22, 2023
Impact of Therapy Management on Axitinib-Related Adverse Events in Patients With Advanced Renal Cell Carcinoma Receiving First-Line Axitinib + Checkpoint InhibitorYousef Zakharia, Lynn Huynh, Shawn Du, et al.
Future Oncology (London, England)|June 11, 2024
Real-world clinical outcomes among patients with metastatic castration-sensitive prostate cancer initiating apalutamideBenjamin H Lowentritt, Shawn Du, Carmine Rossi, et al.
Advances in Therapy|November 28, 2025
Response to Letter to the Editor Regarding: 'Overall Survival with Apalutamide Versus Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer'Mehmet A Bilen, Benjamin Lowentritt, Ibrahim Khilfeh, et al.
Advances in Therapy|May 29, 2025
Overall Survival with Apalutamide Versus Enzalutamide in Metastatic Castration-Sensitive Prostate CancerMehmet A Bilen, Benjamin Lowentritt, Ibrahim Khilfeh, et al.
Journal of Comparative Effectiveness Research|May 9, 2025
Overall survival in patients with metastatic castration-sensitive prostate cancer treated with apalutamide versus abiraterone acetate: a head-to-head analysis of real-world patients in the USABenjamin Lowentritt, Mehmet A Bilen, Ibrahim Khilfeh, et al.
ERJ Open Research|August 6, 2024
Burden of eosinophilic granulomatosis with polyangiitis in EuropeRupert W Jakes, Namhee Kwon, Lynn Huynh, et al.
Urologic Oncology|April 20, 2023
Comparison of prostate-specific antigen response in patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or abiraterone acetate: A retrospective cohort studyBenjamin Lowentritt, Dominic Pilon, Dexter Waters, et al.
Journal of Medical Economics|July 15, 2025
Healthcare resource utilization and costs among patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or enzalutamide in the United States (2019-2023)Mehmet A Bilen, Benjamin Lowentritt, Sabree Burbage, et al.
Clinical and Translational Gastroenterology|February 15, 2024
Clinical Outcomes Before and After Prucalopride Treatment: An Observational Study in Patients With Chronic Idiopathic Constipation in the United StatesAnthony Lembo, Brooks D Cash, Mei Lu, et al.
Gastro Hep Advances|June 10, 2025
Economic Burden of Patients With Chronic Idiopathic Constipation in the USA Before and After Prucalopride InitiationPaul Feuerstadt, Mei Lu, Emi Terasawa, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Clinical Genitourinary Cancer|April 22, 2023
Impact of Therapy Management on Axitinib-Related Adverse Events in Patients With Advanced Renal Cell Carcinoma Receiving First-Line Axitinib + Checkpoint InhibitorYousef Zakharia, Lynn Huynh, Shawn Du, et al.
Future Oncology (London, England)|June 11, 2024
Real-world clinical outcomes among patients with metastatic castration-sensitive prostate cancer initiating apalutamideBenjamin H Lowentritt, Shawn Du, Carmine Rossi, et al.
Advances in Therapy|November 28, 2025
Response to Letter to the Editor Regarding: 'Overall Survival with Apalutamide Versus Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer'Mehmet A Bilen, Benjamin Lowentritt, Ibrahim Khilfeh, et al.
Advances in Therapy|May 29, 2025
Overall Survival with Apalutamide Versus Enzalutamide in Metastatic Castration-Sensitive Prostate CancerMehmet A Bilen, Benjamin Lowentritt, Ibrahim Khilfeh, et al.
Journal of Comparative Effectiveness Research|May 9, 2025
Overall survival in patients with metastatic castration-sensitive prostate cancer treated with apalutamide versus abiraterone acetate: a head-to-head analysis of real-world patients in the USABenjamin Lowentritt, Mehmet A Bilen, Ibrahim Khilfeh, et al.
ERJ Open Research|August 6, 2024
Burden of eosinophilic granulomatosis with polyangiitis in EuropeRupert W Jakes, Namhee Kwon, Lynn Huynh, et al.
Urologic Oncology|April 20, 2023
Comparison of prostate-specific antigen response in patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or abiraterone acetate: A retrospective cohort studyBenjamin Lowentritt, Dominic Pilon, Dexter Waters, et al.
Journal of Medical Economics|July 15, 2025
Healthcare resource utilization and costs among patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or enzalutamide in the United States (2019-2023)Mehmet A Bilen, Benjamin Lowentritt, Sabree Burbage, et al.
Clinical and Translational Gastroenterology|February 15, 2024
Clinical Outcomes Before and After Prucalopride Treatment: An Observational Study in Patients With Chronic Idiopathic Constipation in the United StatesAnthony Lembo, Brooks D Cash, Mei Lu, et al.
Gastro Hep Advances|June 10, 2025
Economic Burden of Patients With Chronic Idiopathic Constipation in the USA Before and After Prucalopride InitiationPaul Feuerstadt, Mei Lu, Emi Terasawa, et al.
Pageof 3